BRD4-TARGETED THERAPY ABBV-744 CLINICAL DATA NO FURTHER A MYSTERY

In Segment A, participants will obtain unique doses and schedules of oral ABBV-744 pill to establish Harmless dosing routine. Further participants is going to be enrolled on the identified monotherapy dosign program. In Segment B, contributors will obtain oral ruxolitinib and ABBV-744 will likely be offered as "increase-on" therapy. In Section C, c